CA2924953C - Process for producing diazabicyclooctane derivative and intermediate thereof - Google Patents

Process for producing diazabicyclooctane derivative and intermediate thereof Download PDF

Info

Publication number
CA2924953C
CA2924953C CA2924953A CA2924953A CA2924953C CA 2924953 C CA2924953 C CA 2924953C CA 2924953 A CA2924953 A CA 2924953A CA 2924953 A CA2924953 A CA 2924953A CA 2924953 C CA2924953 C CA 2924953C
Authority
CA
Canada
Prior art keywords
benzyloxy
tert
amino
compound represented
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2924953A
Other languages
English (en)
French (fr)
Other versions
CA2924953A1 (en
Inventor
Takao Abe
Takeshi Furuuchi
Yoshiaki Sakamaki
Nakako Mitsuhashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meiji Seika Pharma Co Ltd
Original Assignee
Meiji Seika Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Pharma Co Ltd filed Critical Meiji Seika Pharma Co Ltd
Publication of CA2924953A1 publication Critical patent/CA2924953A1/en
Application granted granted Critical
Publication of CA2924953C publication Critical patent/CA2924953C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CA2924953A 2013-09-24 2014-09-24 Process for producing diazabicyclooctane derivative and intermediate thereof Active CA2924953C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013-197110 2013-09-24
JP2013197110 2013-09-24
PCT/JP2014/075203 WO2015046207A1 (ja) 2013-09-24 2014-09-24 ジアザビシクロオクタン誘導体の製造法とその中間体

Publications (2)

Publication Number Publication Date
CA2924953A1 CA2924953A1 (en) 2015-04-02
CA2924953C true CA2924953C (en) 2021-12-07

Family

ID=52743343

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2924953A Active CA2924953C (en) 2013-09-24 2014-09-24 Process for producing diazabicyclooctane derivative and intermediate thereof

Country Status (22)

Country Link
US (2) US10000491B2 (https=)
EP (1) EP3050883B1 (https=)
JP (1) JP6453222B2 (https=)
KR (1) KR102239725B1 (https=)
CN (2) CN107501264A (https=)
AR (5) AR097744A1 (https=)
AU (1) AU2014324302B2 (https=)
BR (1) BR112016006246B8 (https=)
CA (1) CA2924953C (https=)
DK (1) DK3050883T3 (https=)
ES (1) ES2793201T3 (https=)
HK (1) HK1244487A1 (https=)
HU (1) HUE049027T2 (https=)
IL (1) IL244740B (https=)
MX (2) MX372585B (https=)
MY (2) MY176278A (https=)
NZ (1) NZ718009A (https=)
RU (1) RU2719480C2 (https=)
SG (1) SG11201602256UA (https=)
TW (1) TWI644908B (https=)
WO (1) WO2015046207A1 (https=)
ZA (1) ZA201602053B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2693898C2 (ru) 2012-05-30 2019-07-05 Мейдзи Сейка Фарма Ко., Лтд. НОВЫЙ ИНГИБИТОР бета-ЛАКТАМАЗЫ И СПОСОБ ЕГО ПОЛУЧЕНИЯ
DK3050883T3 (da) 2013-09-24 2020-05-25 Meiji Seika Pharma Co Ltd Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter
EP3613740A1 (en) 2013-10-08 2020-02-26 Meiji Seika Pharma Co., Ltd. Preparation of a diazabicyclooctane derivative
RU2732129C2 (ru) * 2014-12-05 2020-09-11 Мейдзи Сейка Фарма Ко., Лтд. Способ производства кристаллов производного диазабициклооктана и стабильного лиофилизированного препарата
CA2944306C (en) 2015-10-30 2023-11-14 The Toronto-Dominion Bank Validating encrypted data from a multi-layer token
US11216808B2 (en) 2015-11-04 2022-01-04 The Toronto-Dominion Bank Token-based system for excising data from databases
JP2020011901A (ja) * 2016-10-20 2020-01-23 協和キリン株式会社 ピロリジン化合物の製造方法
CN106699756B (zh) * 2016-12-30 2019-10-29 淄博鑫泉医药技术服务有限公司 β内酰胺酶抑制剂阿维巴坦的合成方法
US10584123B2 (en) 2017-09-27 2020-03-10 Fedora Pharmaceuticals Inc. Pharmaceutical forms of diazabicyclooctane derivatives and manufacturing method thereof
WO2019064065A1 (en) 2017-09-27 2019-04-04 F. Hoffmann-La Roche Ag PHARMACEUTICAL FORMS OF DIAZABICYCLOOCTANE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
KR20200091395A (ko) 2017-09-27 2020-07-30 페도라 파마슈티칼스 인코포레이티드 디아자비시클로옥탄 유도체의 결정형 및 그의 제조 방법
CN109678856B (zh) * 2017-10-18 2020-09-25 新发药业有限公司 一种阿维巴坦中间体的制备方法
CN111373033A (zh) 2017-11-23 2020-07-03 豪夫迈·罗氏有限公司 脯氨酸羟化酶及其相关用途、方法和产品
WO2020018462A1 (en) 2018-07-16 2020-01-23 Brown University A chromogenic beta-lactamase substrate
CN119707784A (zh) * 2018-09-21 2025-03-28 株式会社Api 氨基酸衍生物的制备方法
US12195755B2 (en) 2019-05-20 2025-01-14 Brown University Placental lipid bilayer for cell-free molecular interaction studies
US11751775B2 (en) 2019-08-30 2023-09-12 DePuy Synthes Products, Inc. Electrical device for monitoring, prevention, and treatment of implant infections
WO2021087008A1 (en) 2019-10-28 2021-05-06 Brown University Bacterial beta-lactamase responsive hydrogels
CN121021508B (zh) * 2025-10-29 2026-02-24 北京耀诚惠仁科技有限公司 β-内酰胺酶抑制剂中间体共晶或盐及其制备方法和应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5038509B1 (https=) 1970-10-21 1975-12-10
JPS538509A (en) 1976-07-13 1978-01-26 Toshiba Corp Impedance matching system for data transmission circuit
JPS6019759B2 (ja) 1977-11-24 1985-05-17 イ−ライ・リリ−・アンド・カンパニ− 非経口投予用11115152139199東京都中央区京橋2丁目3番13号
GB1589317A (en) 1977-11-24 1981-05-13 Lilly Co Eli Freeze drying cephalothin sodium
JPS60255723A (ja) 1984-05-31 1985-12-17 Ono Pharmaceut Co Ltd メシル酸ガベキサートの結晶性凍結乾燥製剤及びその製造方法
JPH07117533B2 (ja) 1985-08-28 1995-12-18 株式会社生体科学研究所 トランスフエリンおよびその用途
US20030220521A1 (en) 1989-07-27 2003-11-27 G.D. Searle & Co. Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension
TW264475B (https=) 1991-09-20 1995-12-01 Takeda Pharm Industry Co Ltd
HUT74682A (en) * 1993-12-29 1997-01-28 Pfizer Diazabicyclic neurokinin antagonists and pharmaceutical compositions containing them
JP2843444B2 (ja) 1994-05-02 1999-01-06 塩野義製薬株式会社 ピロリジルチオカルバペネム誘導体の結晶,該結晶を含む凍結乾燥製剤,およびその製造方法
WO1995029913A1 (en) 1994-05-02 1995-11-09 Shionogi & Co., Ltd. Crystal of pyrrolidylthiocarbapenem derivative, lyophilized preparation containing said crystal, and process for producing the same
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2815420B1 (fr) 2000-10-16 2003-05-16 Cit Alcatel Compensation de la dispersion chromatique dans un systeme de transmission a fibre optique, et fibre de compensation
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2921060B1 (fr) 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
ES2533826T3 (es) 2008-01-18 2015-04-15 Merck Sharp & Dohme Corp. Inhibidores de beta-lactamasa
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
US20120053350A1 (en) 2009-04-30 2012-03-01 Ian Mangion Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
JP2012122603A (ja) 2010-11-15 2012-06-28 Nifco Inc コネクタ装置
SI2657234T1 (sl) * 2010-12-22 2017-06-30 Meiji Seika Pharma Co., Ltd. Derivat optično-aktivnega diazabiciklooktana in metoda za njegovo izdelavo
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
KR102143660B1 (ko) * 2011-06-17 2020-08-11 화이자 안티-인펙티브스 에이비 트랜스-7-옥소-6-(술포옥시)-1,6-디아자비시클로[3,2,1]옥탄-2-카르복스아미드 및 그의 염을 포함하는 헤테로시클릭 화합물의 제조 방법
RU2578370C2 (ru) 2011-08-27 2016-03-27 Вокхардт Лимитед Производные 1,6- диазабицикло [3,2,1] октан-7-она и их применение при лечении бактериальных инфекционных болезней
MX340533B (es) 2011-08-30 2016-07-13 Wockhardt Ltd Derivados de 1,6- diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
EP3052497B1 (en) 2011-09-13 2017-06-28 Wockhardt Limited Nitrogen containing compounds and their use
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
RU2693898C2 (ru) 2012-05-30 2019-07-05 Мейдзи Сейка Фарма Ко., Лтд. НОВЫЙ ИНГИБИТОР бета-ЛАКТАМАЗЫ И СПОСОБ ЕГО ПОЛУЧЕНИЯ
DK3050883T3 (da) 2013-09-24 2020-05-25 Meiji Seika Pharma Co Ltd Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter
EP3613740A1 (en) 2013-10-08 2020-02-26 Meiji Seika Pharma Co., Ltd. Preparation of a diazabicyclooctane derivative

Also Published As

Publication number Publication date
CN105555787B (zh) 2017-08-08
KR102239725B1 (ko) 2021-04-12
TWI644908B (zh) 2018-12-21
EP3050883A4 (en) 2017-05-10
MX372585B (es) 2020-04-17
US10000491B2 (en) 2018-06-19
CN107501264A (zh) 2017-12-22
CN105555787A (zh) 2016-05-04
MY193210A (en) 2022-09-26
EP3050883A1 (en) 2016-08-03
RU2016115767A3 (https=) 2018-06-29
WO2015046207A1 (ja) 2015-04-02
MY176278A (en) 2020-07-27
AU2014324302A1 (en) 2016-05-12
MX367578B (es) 2019-08-27
JP6453222B2 (ja) 2019-01-16
BR112016006246B1 (pt) 2021-09-08
US20170283415A1 (en) 2017-10-05
US20160264573A1 (en) 2016-09-15
SG11201602256UA (en) 2016-04-28
KR20160058851A (ko) 2016-05-25
NZ718009A (en) 2018-03-23
ZA201602053B (en) 2019-06-26
US10000492B2 (en) 2018-06-19
EP3050883B1 (en) 2020-04-22
HUE049027T2 (hu) 2020-08-28
AR131186A2 (es) 2025-02-26
AR131189A2 (es) 2025-02-26
AR131188A2 (es) 2025-02-26
IL244740B (en) 2018-11-29
MX2016003867A (es) 2016-08-04
RU2016115767A (ru) 2017-10-26
IL244740A0 (en) 2016-04-21
CA2924953A1 (en) 2015-04-02
ES2793201T3 (es) 2020-11-13
AU2014324302B2 (en) 2018-02-15
JPWO2015046207A1 (ja) 2017-03-09
RU2719480C2 (ru) 2020-04-17
DK3050883T3 (da) 2020-05-25
HK1244487A1 (zh) 2018-08-10
HK1219473A1 (zh) 2017-04-07
BR112016006246A2 (https=) 2017-08-22
AR131190A2 (es) 2025-02-26
AR097744A1 (es) 2016-04-13
BR112016006246B8 (pt) 2021-10-05
TW201546059A (zh) 2015-12-16

Similar Documents

Publication Publication Date Title
CA2924953C (en) Process for producing diazabicyclooctane derivative and intermediate thereof
US12103928B2 (en) Processes for preparing a diazabicyclooctane compound
JP7182677B2 (ja) ジアザビシクロオクタン誘導体の結晶とその製造法
HK1226406A1 (en) Production method for diazabicyclooctane derivatives and intermediates
RU2800050C2 (ru) НОВЫЙ ИНГИБИТОР β-ЛАКТАМАЗЫ И СПОСОБ ЕГО ПОЛУЧЕНИЯ
HK1226406B (en) Production method for diazabicyclooctane derivatives and intermediates
HK1219473B (en) Production method for diazabicyclooctane derivative and intermediary body thereof
HK1208862B (en) Novel -lactamase inhibitor and method for producing same

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190920

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240730

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240730

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250805

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250805